The Opioid Drugs Market, estimated at USD 48.02 Bn in 2025, is expected to exhibit a CAGR of 3.3% and reach USD 60.27 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Key market players are focusing on adopting organic growth strategies such as the launch of new products, which will drive the global Opioid Drugs market. For instance, on July 11, 2025, Fresenius Kabi AG, a global pharmaceutical company, announced that they had launched a new Simplist ready-to-administer prefilled syringe, a Fentanyl Citrate Injection USP in 100 mcg per 2 mL, in the U.S.
Global Opioid Drugs Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.
COVID-19 had a negative impact on the global opioid drugs market as COVID-19 is a respiratory-related disease and the use of opioids is linked with respiratory suppression, leading to a synergistic effect. Thus, the use of opioids in COVID-19 patients led to an increase in respiratory-related deaths. For instance, according to an article published in the National Library of Medicine in April 2025, titled “Impact of the COVID-19 Pandemic on Opioid Overdose Deaths: A Spatiotemporal Analysis,” the study suggests that there was an increase in the number of opioid overdose deaths (OODs) during the pandemic.
Global Opioid Drugs Market: Key Developments
In January 2025, Hikma Pharmaceuticals PLC, a U.K.-based multinational pharmaceutical company, announced that they had launched Naloxone Hydrochloride Injection, USP, 2mg and 2mL, in prefilled syringe (PFS) form. The drug, which was launched in the U.S., is used for the emergency treatment of a known or suspected opioid.
On May 23, 2025, the U.S. Food and Drug Administration (FDA) announced that they had approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, and a monthly version for patients already being treated with buprenorphine.